Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer
Jeffrey How, Shrina Patel, Bryan Fellman, Karen H. Lu, Patrick Hwu, Lois M. Ramondetta, Shannon N. Westin, Nicole D. Fleming, Pamela T. Soliman, Amir A. Jazaeri
Topics & Concepts
MedicineLenvatinibPembrolizumabEndometrial cancerOncologyToxicityInternal medicineCancerGynecologyImmunotherapyThyroid cancerEndometrial and Cervical Cancer TreatmentsGynecological conditions and treatmentsUterine Myomas and Treatments